Burkhard Möller
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügle T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open 2023; 9
01.12.2023Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
01.12.2023RMD Open 2023; 9
Ciurea Adrian, Götschi Andrea, Bräm René, Bürki Kristina, Exer Pascale, Andor Michael, Nissen Michael J, Möller Burkhard, Hügle Thomas, Rubbert-Roth Andrea, Kyburz Diego, Distler Oliver, Scherer Almut, Micheroli Raphael
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, Von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 2023; 13:17776.
18.10.2023Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
18.10.2023Sci Rep 2023; 13:17776
Riek Myriam, Scherer Almut, Möller Burkhard, Ciurea Adrian, Von Mühlenen Ines, Gabay Cem, Kyburz Diego, Brulhart Laure, von Kempis Johannes, Mueller Ruediger B, Hasler Paul, Strahm Tanja, von Känel Sabine, Zufferey Pascal, Dudler Jean, Finckh Axel
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. Clin Rheumatol 2023; 42:2377-2385.
08.06.2023Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
08.06.2023Clin Rheumatol 2023; 42:2377-2385
Micheroli Raphael, Kissling Seraphina, Bürki Kristina, Möller Burkhard, Finckh Axel, Nissen Michael J, Exer Pascale, Bräm René, Kyburz Diego, Rubbert-Roth Andrea, Andor Michael, Baraliakos Xenofon, de Hooge Manouk, Distler Oliver, Scherer Almut, Ciurea Adrian
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.
23.12.2022Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
23.12.2022Rheumatology (Oxford) 2022; 62:89-97
Amstad Andrea, Papagiannoulis Eleftherios, Scherer Almut, Rubbert-Roth Andrea, Finckh Axel, Mueller Ruediger, Dudler Jean, Möller Burkhard, Villiger Peter M, Schulz Martin, Kyburz Diego
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022; 13:1016927.
13.10.2022Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
13.10.2022Front Immunol 2022; 13:1016927
Raptis Catherine E, Berger Christoph T, Ciurea Adrian, Andrey Diego O, Polysopoulos Christos, Lescuyer Pierre, Maletic Tanja, Riek Myriam, Scherer Almut, von Loga Isabell, Safford Judith, Lauper Kim, Möller Burkhard, Vuilleumier Nicolas, Finckh Axel, Rubbert-Roth Andrea
Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis
Manoil D, Courvoisier D, Gilbert B, Möller B, Walker U, Muehlenen I, Rubbert-Roth A, Finckh A, Bostanci N. Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis. Rheumatology (Oxford) 2021; 60:4755-4764.
02.01.2021Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis
02.01.2021Rheumatology (Oxford) 2021; 60:4755-4764
Manoil Daniel, Courvoisier Delphine S, Gilbert Benoit, Möller Burkhard, Walker Ulrich A, Muehlenen Ines Von, Rubbert-Roth Andrea, Finckh Axel, Bostanci Nagihan
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
Ciurea A, Scherer A, Distler O, Kyburz D, Dan D, Müller A, Bräm R, Andor M, Rubbert-Roth A, Möller B, Micheroli R, von Loga I, Bürki K, Papagiannoulis E, Finckh A. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2020; 80:238-241.
22.09.2020Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort
22.09.2020Ann Rheum Dis 2020; 80:238-241
Ciurea Adrian, Scherer Almut, Distler Oliver, Kyburz Diego, Dan Diana, Müller Angela, Bräm René, Andor Michael, Rubbert-Roth Andrea, Möller Burkhard, Micheroli Raphael, von Loga Isabell, Bürki Kristina, Papagiannoulis Eleftherios, Finckh Axel
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlenen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology (Oxford) 2017; 56:1579-1585.
01.09.2017Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
01.09.2017Rheumatology (Oxford) 2017; 56:1579-1585
Alpizar-Rodriguez Deshiré, Gabay Cem, Courvoisier Delphine S, Lamacchia Céline, Mahler Michael, Roux-Lombard Pascale, Von Mühlenen Ines, Walker Ulrich A, Kyburz Diego, Zufferey Pascal, Ciurea Adrian, Dudler Jean, Möller Burkhard, Müller Rüdiger, Finckh Axel
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlenen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clin Rheumatol 2017
21.01.2017The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
21.01.2017Clin Rheumatol 2017
Alpizar-Rodriguez D, Bas Sylvette, Gascon Danielle, Lamacchia Céline, Roux-Lombard Pascale, Lauper Kim, Nissen Michael J, Courvoisier Delphine S, Gabay Cem, Mahler Michael, Zufferey Pascal, Brulhart Laure, Müller Rüdiger, Möller Burkhard, Dudler Jean, Ciurea Adrian, Walker Ulrich A, Von Mühlenen Ines, Kyburz Diego, Finckh Axel
Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Res Ther 2016; 18:88.
14.04.2016Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
14.04.2016Arthritis Res Ther 2016; 18:88
Müller Rüdiger, Gengenbacher Michael, Richter Symi, Dudler Jean, Möller Burkhard, von Kempis Johannes
The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists
Boehncke W, Yawalkar N, Villiger P, Navarini A, Möller B, Michel B, Laffitte E, Kyburz D, Häusermann P, Hasler P, Hasler F, Dudler J, Conrad C, Anliker M, Gabay C. The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists. Dermatology (Basel) 2015; 230:75-81.
06.01.2015The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists
06.01.2015Dermatology (Basel) 2015; 230:75-81
Boehncke Wolf-Henning, Yawalkar Nikhil, Villiger Peter M, Navarini Alexander A, Möller Burkhard, Michel Beat A, Laffitte Emmanuel, Kyburz Diego, Häusermann Peter, Hasler Paul, Hasler Fritz, Dudler Jean, Conrad Curdin, Anliker Mark, Gabay Cem